The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Shares of Sanofi (NASDAQ:SNY) and Roche (OTCQX:RHHBY) were flat in European trading on Thursday after the EU pharma giants ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit ...